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Abstract
Background: Environmental estrogens are exogenous estrogen-mimicking compounds that can interfere with
endogenous endocrine systems. Several of these endocrine disruptors have been shown to alter normal
development and influence tumorigenesis in experimental models. N-butyl benzyl phthalate (BBP), a widely used
plasticizer, is a well-known endocrine disruptor. The aim of this study was to elucidate the effect of prenatal
exposure to BBP on the morphology, proliferative index, and genomic signature of the rat mammary gland at
different ages.
Methods: In utero exposure was performed by gavage of pregnant Sprague Dawley CD rats with 120mg or 500mg
BBP/kg/day from day 10 post-conception to delivery. Female litters were euthanized at 21, 35, 50 and 100 days.
The morphology and proliferative index of the mammary gland were studied from whole mount preparations and
BrdU incorporation, respectively. Gene expression profile was assessed by microarrays. Several genes found
differentially expressed and related to different functional categories were further validated by real time RT-PCR.
Results: Prenatal exposure of BBP induced delayed vaginal opening and changes in the post-natal mammary
gland long after the end of the treatment, mainly by 35 days of age. Exposure to the high dose resulted in
modifications in architecture and proliferative index of the mammary gland, mostly affecting the undifferentiated
terminal end buds. Moreover, the expression profiles of this gland in the exposed rats were modified in a dose-
dependent fashion. Analysis of functional categories showed that modified genes were related to immune
function, cell signaling, proliferation and differentiation, or metabolism.
Conclusions: Our data suggest that in utero exposure to BBP induced a delayed pubertal onset and modified
morphology of the mammary gland. These alterations were accompanied by modifications in gene expression
previously associated with an increased susceptibility to carcinogenesis.
Background
Phthalates are widely used plasticizers that have gener-
ated growing concern for their potential adverse effect
on human health. Compounds such as butyl benzyl
phthalate (BBP), commonly used in vinyl tile among
other products, have been shown to be potential toxi-
cants in rats [1]. In vivo models, especially involving
rats, have proven to be a good tool for investigating the
effect of environmental compounds on health, and thus
obtaining evidence of the potential risk of such com-
pounds on humans. Sprague-Dawley rats are widely
used in toxicological and risk assessment studies due to
the fact that they have a metabolism similar to humans
[2]. Perinatal exposure of rats to BBP and its major
metabolite, monobenzyl phthalate, has been shown to
have an antiandrogenic effect, inducing significant
alterations in the reproductive system of male offspring.
A few published studies have also observed the effects
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any medium, provided the original work is properly cited.of BBP in females, such as alterations in ovarian weight
and anogenital distance [3], or modifications in the pro-
gesterone receptor expression in the preoptic area [4].
Although the risks of BBP to human health are con-
troversial, the European Commission has banned BBP
from toys and child care items because of its reproduc-
tive toxicity [5]. BBP is one of the phthalates studied by
the National Toxicology Program (NTP) Center for the
Evaluation of Risks to Human Reproduction (CERHR),
concluding that there was minor concern for adverse
reproductive effects in exposed men, but the data in
women were insufficient [6]. BBP has been suggested to
have an etiological association with endometriosis, as
the severity of this condition and BBP concentration in
blood have been strongly correlated [7]. Moreover, urin-
ary concentrations of phthalate metabolites in pregnant
mothers have been inversely correlated to anogenital
distance among male infants, providing a demonstration
of subtle developmental effects of prenatal exposure to
phthalates in humans [8]. Fetal life is considered to be
the most sensitive stage to the potential developmental
and reproductive toxicity of the phthalates, but data on
human fetal exposure to phthalates is still scarce [9].
All these lines of evidence point out BBP as an endo-
crine disrupting chemical, suggesting that it may inter-
fere with the endocrine system and thus disrupt normal
function in hormone-sensitive organs [10]. Several
mechanisms have been proposed for the antiandrogenic
effect of BBP in males, such as the decrease of testoster-
o n eb yc h a n g e si nt h eg e n ee x p r e s s i o no fg e n e sr e l a t e d
to the hormone synthesis and transport [11-13], or the
down-regulation of Insl3 in the Leydig cells, which has a
direct role in testis descent into the scrotal sac [14].
Although there is little data regarding the effects of BBP
in females, other phthalates have been observed to
decrease serum estradiol levels, prolong estrous cycles,
and cause anovulation in adult cycling rats, acting
through a receptor-mediated signaling pathway to sup-
press estradiol production in the ovary [15]. Endocrine
disruptors may have an effect in other hormone-
sensitive organs, such as the mammary gland. The breast
t i s s u ei ss t r o n g l yi n f l u e n c e db ye s t r o g e n s ,w h i c hh a v ea n
essential role in promoting the proliferation of both the
normal and the neoplastic mammary epithelium. The
response of the mammary gland to hormonal influences
results in developmental changes that can permanently
modify the architecture and the biological characteristics
of the gland, and changes in the estrogenic environment
during the critical stages of development can play a role
in the future susceptibility to develop breast cancer
[16,17]. Elevated estrogenic exposure in utero has been
associated to an increase in breast cancer risk in both
humans and animal models [10,18]. We have previously
reported that neonatal and prepubertal exposure to BBP
has little influence in the morphology of the mammary
gland yet induced transitory changes in the gene expres-
sion profile of the gland [19], but new data is needed in
relation to in utero exposure. More studies on mam-
mary cancer susceptibility can provide an insight into
the risk of breast cancer, the most common type of
malignancy in women worldwide, whose rates are
increasing in most countries [20]. The Sprague-Dawley
rat is a good model for the study of breast cancer, and
we have previously reported the validity of this model
for the study of breast cancer in women [21]. The pre-
sent work investigated the effect of prenatal exposure of
BBP on the rat mammary gland. Fetuses were exposed
to the BBP via oral gavage (120 mg or 500 mg BBP/
body weight) given to their pregnant mothers, hence it
is estimated that they receive 1/100 to 1/1000 of the
mother dose. This approximation places this exposure
near the EPA safe dose for humans of 0.2 mg/kg/day
[22]. Then, we have used morphological parameters of
gland differentiation [16,17], proliferative index, and
genomic signature as biomarkers for detecting how pre-
natal exposure affects the post-natal development of the
mammary gland.
Methods
Animals and experimental design
All animal studies were conducted in the University of
Alabama at Birmingham in accordance with Institutional
Guidelines for Animal Use and Care. Eight week old
female Sprague Dawley CD rats (Charles River, Raleigh
NC) were bred and maintained on phytoestrogen-free
A I N - 9 3 Gd i e t( H a r l a nT e k l a d ,M a d i s o nW I )a tt h e
University of Alabama at Birmingham animal facility.
For prenatal exposure, pregnant female rats (10/treat-
ment group) were gastrically intubated with 120 mg
BBP/kg body weight (BW), 500 mg BBP/BW, or an
equivalent volume of sesame oil on days 10-21 post-
conception. The BBP was obtained from Aldrich with
98% of purity, and it was dissolved in sesame oil. The
doses administered were chosen based on studies by
Singletary et al. [23] where they reported that treatment
of female rats with 250 and 500 mg/kg of BBP for
7 days prior to dosing with DMBA decreased mammary
tumor incidence. The LOAEL (lowest-observable-
adverse-effect levels) of this compound has been deter-
mined at 250mg/kg/day [12]. The offspring were weaned
at day 21. Body weight was recorded and vaginal open-
ing was assessed as an index of maturation.
Female offspring were euthanized at 21, 35, 50 and
100 days of age. For the later three ages, all females
were sacrificed in the estrus phase of the estrous cycle.
The animals were anesthetized with ketamine/xylazine
and the fourth mammary glands were promplty dis-
sected. The “mammary tree” was trimmed free of excess
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offspring from each litter at each time point). Transsec-
tion of the aorta was performed after the tissues were
properly collected. From another set of randomly
selected females from each litter, mammary glands were
dissected for whole mount preparation and gland differ-
entiation analysis, and the contralateral mammary
glands were paraffin-blocked for determination of prolif-
erative index. Ten mammary glands from different ani-
m a l s( f r o md i f f e r e n tl i t t e r s )p e rg r o u pa te a c ht i m e
point were used for each of the morphological, prolifera-
tion and molecular analyses.
Morphological analysis of the mammary gland
The histoarchitecture of the mammary gland was stu-
died from the whole-mounted tissue. The excised glands
were fixed in 10% neutral-buffered formalin, defatted in
acetone, re-hydrated and stained in alum carmine. After
the staining, the glands were dehydrated in a series of
graded alcohols, cleared in xylene and coverslipped with
mounting media. The total number of epithelial struc-
tures (terminal end buds -TEB-, terminal ducts -TD-,
alveolar buds -AB- and lobules type 1 -Lob1-) was
determined under an Olympus microscope using a 40x
magnification objective. These structures were counted
in the zone C (5 mm-exterior zone), opposite to the
nipple, which is the most actively growing area of the
mammary gland [24].
Study of the proliferative index
Animals were injected i.p. with bromodeoxyuridine
(BrdU, Sigma, St. Louis, MO) two hours before euthana-
sia. Cycling animals received the BrdU injection while in
estrus. The abdominal mammary glands were fixed in
10% neutral-buffered formalin, embedded in paraffin
and sectioned at 4 μm thickness. Tissue sections were
mounted on positively charged slides and immuno-
chemically reacted with anti-BrdU monoclonal antibody
(BioGenex, San Ramon, CA) using an automatic slide
stainer (BioGenex). Incorporated BrdU was visualized
using the streptavidin-biotin labeling system with 3, 3’-
diaminobenzidine (DAB) as a color reaction substrate
(BioGenex). The proliferative index was determined
quantitatively under Olympus BX40 microscope (60x
magnification objective) as the percentage of DAB posi-
tive cells within specific epithelial structures, i.e., TEB,
TD and ducts, AB and Lob1. A minimum of 1,000 cells
per structure in each sample was counted.
Characterization of the gene expression profile
Total RNA from the mammary glands was extracted
using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA).
The quantity and integrity of the samples were deter-
m i n e dw i t hN a n o D r o p2 . 5 . 4 .( N a n o D r o pT e c h n o l o g i e s ,
Wilmingon, DE) and by capillary electrophoresis using
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). High quality RNA with absorbance 260/280
greater than 1.8 and RNA integrity number greater than
8 was used for further analysis. The ten RNA samples
from each group at each time point were reduced to
four different pooled samples for cDNA microarrays
hybridization. Fluorescent cRNA probes were synthe-
sized with the Agilent Low Input RNA Fluorescent Lin-
ear Amplification Kit (Agilent Technologies) in the
presence of Cy3-dCTP or Cy5-dCTP (Perkin Elmer,
Wellesley, MA), and purified using the RNeasy Mini Kit
(Qiagen Inc., Valencia, CA). Agilent 60-mer oligo-
microarrays containing 22,000 sequences were hybri-
dized with 750 ng of Cy3 labeled control probe and
750 ng of Cy5 labeled BBP group probe at 60°C for
18 hours. Slides were washed, scanned, and submitted
to Feature Extraction software v.9.0 (Agilent Technolo-
gies) using the defaults settings for background correc-
tion and normalization. The processed signals acquired
from Feature Extraction were used for statistical analysis
and expression values of individual arrays were com-
bined by the average across the biological replicates.
Spots with any quality issues were omitted from the
analysis. To identify the genes differentially expressed
each group treated with BBP was compared to its age-
matched untreated control using empirical Bayes mod-
erated t-test, implemented in the Bioconductor package
“limma” [25,26]. For each comparison, all probes that
presented at least 1.5-fold change (0.6 logarithm in base
two) and with False Discovery Rate (FDR) less than 0.05
were considered statistically significant. The up- or
down-regulated genes were classified by their biological
processes according to Gene Ontology (GO) database
and tested for over-representation using the Protein
ANalysis THrough Evolutionary Relationships
(PANTHER) functional analysis tool. Each list was sta-
tistically compared to NCBI: R. norvegicus genes refer-
ence list using the binomial test and the Bonferroni
correction for multiple testing.
Real time RT-PCR
To validate results of the microarrays we analyzed the
expression of several genes found differentially
expressed in the mammary glands of rats exposed pre-
natally to BBP by real-time reverse transcription PCR.
All reactions were performed on the ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA) using the fluorescent TaqMan methodology
(TaqMan One Step RT-PCR Master Mix Reagents,
Applied Biosystems). The kit employs AmpliTaq Gold
®
DNA polymerase for enhanced performance, Passive
Reference I, and optimized buffer components. 100 ng
of total RNA from individual samples was used for each
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facturer’s protocol. The thermal cycling conditions com-
prised 30 min at 48°C, 10 min at 95°C, and 40 cycles of
15 s denaturation at 95°C and 60 s annealing at 60°C.
Each gene was normalized using beta-actin as a control
gene.
Statistical methods
Statistical analyses were performed with the SPSS software
(version 15.0). Since variables followed a normal distribu-
tion, determined by the Kolmogorov-Smirnov test, and
had the equality of variances among groups, determined
by Levene’s test, parametric analyses were carried out.
Results from body weight analysis, vaginal opening, mam-
mary gland morphology and proliferation were analyzed
using ANOVA followed by Tukey’s post hoc test for mul-
tiple comparisons. Analysis for real time PCR was per-
formed using two-sample two-tailed unpaired t-test. Data
for microarrays was analyzed as indicated above. Differ-
ences were considered significant when P < 0.05.
Results
Effects of in utero exposure of BBP on body weights and
sexual maturation
In utero exposure to low or high dose of BBP did not
modify the body weight at 21, 35, 50 or 100 post-natal
days (data not shown), or at day of vaginal opening.
However, exposure to high dose of BBP significantly
retarded the vaginal opening by two days (Table 1).
Effects of in utero exposure of BBP on mammary gland
morphology
The number of terminal ductal structures, i.e., TEB, AB,
T D ,a n dL o b1 ,w e r ea n a l y z e di nw h o l e - m o u n t e dm a m -
mary glands at 21, 35, 50 and 100 post-natal days. The
number of undifferentiated TEB decreased from 21 to 100
days in all groups (Figure 1A), while the TD increased
over time (Figure 1B). The amount of AB began to
increase at 21 days and reached a peak by 35 day decreas-
ing thereafter (Figure 1C). The number of Lob1 also
increased from 21 to 50 days, remaining at about the same
number through 100 days (Figure 1D). Prenatal exposure
to the high dose of BBP increased the number of TD in
relation to control (p = 0.003) and the low dose group
(p = 0.005) at 21 days, as well as it increased the number
of AB in comparison with the control group (p = 0.02) at
35 days. The high dose group also showed a trend to
increase the number of TEB by 50 days, but this result
was not statistically significant (p = 0.093).
Effects of in utero exposure of BBP on proliferative index
The percentage of proliferating cells, as detected by the
incorporation of BrdU into the newly synthesized DNA,
is shown in Figure 2. By 21 days of age the TEB was the
epithelial structure with the highest proliferation index
in all groups. The proliferation of this structure was
higher in the high dose group than in the control group
by 21 (close to significance, p = 0.067) and 35 days (p =
0.010) (Figure 2A). The proliferative index of TEB by
100 days could not be determined since the presence of
this structure at this age was too low to be detected
(Figure 2A). The percentage of proliferating cells in TD
and ducts was lower by 21 days, had increased by 35
and 50 days, and decreased by 100 days; at this last age
the values from low dose group were higher compared
to those in the control group (Figure 2B). There were
not significant differences in the proliferative index in
AB among the BBP-treated and control groups (Figure
2C). In Lob1 the percentage of proliferating cells were
high by 35 and 50 days, and decreased in 100 days-old
animals from all groups. At this last age the proliferative
index was significantly higher in the BBP exposed group
(high dose) than in controls (p = 0.004) (Figure 2D).
Gene expression analysis by microarrays
T h eg e n ee x p r e s s i o na n a l y s i so ft h em a m m a r yg l a n d s
from prenatally BBP-treated rats showed differentially
expressed genes by 35 days of age. Thus, at that age the
low dose induced the up-regulation of 50 genes and
decreased the expression of 335 genes, while the high
dose of BBP increased the expression of 561 genes and
down-regulated 799 genes. The known genes found as
differentially expressed by effect of low and high dose
are shown in Additional File 1, Table S1 and Additional
File 2, Table S2, respectively. When analyses were per-
formed at FDR < 0.1 we found 104 up-regulated and
169 down-regulated genes at PND21 in the mammary
glands of the animals exposed to the low dose of BBP
(data not shown).
The function of the genes differentially expressed was
annotated according to Gene Ontology database. The
main functional categories that were significantly (p <
0.05) over-represented for each cluster of genes when
compared to the gene database for Rattus norvegicus are
indicated in Table 2 (low dose of BBP) and Table 3
(high dose of BBP). Additional File 3, Table S3 details
all functional categories found significantly over- or
Table 1 Maturation parameters of female rats exposed
prenatally to low (120 mg/kg BW) or high (500 mg/kg
BW) dose of BBP
Control BBP low
dose
BBP high
dose
Day of vaginal opening 31.46 ± 0.55 31.30 ± 0.30 33.28 ± 0.29*
Body weight (g) at day
of vaginal opening
116.8 ± 3.7 116.8 ± 4.0 119.1 ± 4.0
Values are mean ± standard error of the mean. * p < 0.05, significantly
different from control.
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both exposures to BBP.
Gene expression analysis by real time RT-PCR
For validation of the sequences found differentially
expressed in the analyses of the microarrays, we per-
formed real time RT-PCR of a number of genes that are
related to several functional categories significantly over-
represented, including those involved in developmental
process (specifically mammary gland differentiation,
such as Csn3, Lalba, Mfge8, and Wap), proliferation
(Bhlhb3), immune system (Cd24, Cd5, Ctse, Ptprc, and
Slpi), lipid metabolism (Thedc1), signal transduction
(Prkcq) and response to stress (Ddit4 and Cryab). Sev-
eral of those genes were also annotated in other func-
tional categories, such as cell adhesion (Mfge8, Cd5),
apoptosis (Lalba, Prkcq, Ddit4, Cryab), transport (Mfge8,
Cd5) or other metabolic processes (Slpi, Cryab).
Results of the real time RT-PCR analyses are shown in
Figure 3. Overall, both doses decreased mammary
differentiation markers (Csn3, Mfge8, Lalba or Wap),
immune related genes, especially the high dose group
(Cd24, Ptprc, Cd5 or Ctse), Bhlhb3 and Ddit4. Both
doses also increased significantly the expression of
Cryab.
Discussion
I nt h i ss t u d yw ef o u n dt h a tin utero exposure to BBP
significantly affects post-natal maturation of female rats,
including delayed vaginal opening, changes in morphol-
ogy of the mammary gland, and changes in gene expres-
sion of the mammary gland at puberty. These effects
were dose-dependent, and the alterations of the mam-
mary gland were age-specific.
Our findings demonstrate that prenatal exposure of
BBP causes a significant delay in female sexual maturity
as determined by the day of vaginal opening associated
with a delayed pubertal onset. Other authors have
reported changes in the time of vaginal opening by
prenatal plus prepubertal exposure to BBP by
Figure 1 Morphological analyses of the mammary gland. Number of epithelial structures, i.e. TEB (A), TD (B), AB (C) and Lob1 (D), at different
ages in the mammary gland of rats exposed prenatally to low or high dose of BBP. *: significant differences (p < 0.05).
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[27], as well as modifications in the anogenital distance
of rats exposed prenatally by oral gavage to the pregnant
dams with 100 mg BBP/kg body weight [28]. Another
indicator of sexual maturity is the morphological and
cellular changes of mammary gland. We observed that
rats exposed prenatally to the higher dose of BBP had a
higher number of undifferentiated epithelial structures
in the mammary gland mainly at the age of pubertal
onset (35 days). This is in accordance with the delay in
the time of vaginal opening and may suggest changes in
the normal development of the mammary gland. More-
over, we found that in all epithelial structures, except in
TD, the proliferative index in BBP-exposed animals was
maximal by 35 days, in contrast to control animals,
which had the highest proliferation indexes by 50 days.
More importantly, exposure to the high dose of BBP
induced more proliferating TEB by 35 days when
compared to unexposed animals. The TEB is the least
differentiated epithelial structure in the mammary gland,
and the most susceptible to malignant transformation
[29]. Thus, alterations in number and/or proliferation of
TEB may cause the changes in susceptibility of this
gland to malignant transformation. For instance, we
have previously demonstrated that both pregnancy and
treatment of virgin rats with the placental hormone
human chorionic gonadotropin (hCG) protected rat
mammary gland from chemically-induced malignant
transformation and that this effect was resulted from
elimination of undifferentiated TEB and inhibition of
cell proliferation [16,17]. It has been described that the
age of highest susceptibility of this gland to chemically-
induced carcinogenesis is around 50 days, when the
TEB are more proliferative [17]. The fact that the BBP-
exposed animals showed more TEB and AB and more
proliferating cells by 35 days suggests that BBP can
Figure 2 Proliferative index in the mammary gland. Percentage of proliferating cells in TEB (A), TD and ducts (B), AB (C) and Lob1 (D) at
different ages in the mammary gland of rats exposed prenatally to low or high dose of BBP. Proliferating cells were identified by
immunohistochemical detection of BrdU incorporation (brown cells). Olympus BX40 microscope with 40x objective. *: significant differences
(p < 0.05).
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tissues, expanding or shifting the window of susceptibil-
ity of the gland to transformation.
The changes in the susceptibility of the mammary
gland to chemically-induced carcinogenesis are likely
resulted from the alterations in specific genomic signa-
ture. Thus, we have studied the gene expression profiles
of the mammary glands from the rats exposed prenatally
to the low and the high doses of BBP. In accordance to
the results of puberty onset, morphology and prolifera-
tive index of the mammary gland, we found changes in
t h eg e n ee x p r e s s i o np r o f i l eo ft h eg l a n d sb y3 5d a y so f
age. The effect of xenobiotics with a putative endocrine-
disrupting influence seems to depend on time of expo-
sure. Thus, we previously observed that treatment with
the same high dose of BBP during the neonatal and lac-
tational periods caused transitory changes in the gene
expression profile of the gland, inducing a high number
of up-modulated genes by 21 days of age (just after the
e n do ft h ee x p o s u r e )b u tn o ta to t h e ra g e s ,a n dn o
changes in the day of vaginal opening [19]. In utero
exposure to 250 μg of bisphenol A (BPA), another endo-
crine disruptor widely used, also induced time-specific
changes in the gene expression profile of the mammary
gland [30], protein expression [31], and shifted the win-
dows of susceptibility for mammary carcinogenesis [32].
Different effects were observed when the same dose was
administrated during the lactational period (neonatal +
prepubertal), finding increased proliferation and
decreased apoptosis in the mammary glands at 50 days,
but not at 21 days [33].
The function of genes dysregulated at puberty by
effect of in utero exposure to BBP included developmen-
tal and immune system processes, metabolism, signaling
or apoptosis. For example, we observed a down-modula-
tion of the immune-related genes Cd5, Cd3d, Ptprc,
especially by effect of the higher dose. Other authors
have also suggested an influence of phthalates on immu-
nity. BBP inhibited lipopolysaccharide-induced TNF-
alpha in a mouse macrophage cell line [34], and human
case-control data have associated the concentration of
BBP in house dust with allergic symptoms [35]. We also
observed at 35 days a down-modulation of genes related
to developmental processes in the BBP-exposed rats,
including mammary gland differentiation markers
(casein kappa -Csn3-, lactalbumin alpha -Lalba-, whey
acidic protein -Wap- and milk fat globule-EGF factor 8
protein -Mfge8 or lactadherin-). Other genes annotated
to “cell proliferation and differentiation” category have
been found down-regulated at that age. That is the case
of Bhlhb3, a transcription factor that is involved in cir-
cadian rhythm, differentiation, and that has been
reported to repress the transcription of cyclin D1 and
thus inhibit proliferation [36]. These results are in
agreement with the ones obtained in the proliferation
analysis (more proliferative structures by 35 days in the
BBP-exposed groups). In relation to this, we have also
found a down-modulation of genes related to apoptosis
(such as lactalbumin [37]) and up-modulation of Cryab,
which has been described to have anti-apoptotic effects
[38]. Hence, our results are compatible with a decreased
apoptosis, as it has been described for other endocrine
disruptors such as BPA [33]. All these data suggest a
proliferation/apoptosis balance tilted to proliferation in
the mammary glands of the exposed rats, and that TEB
may be more susceptible to malignant transformation at
35 days of age.
Prenatal BBP treatment also induced modifications in
the expression of genes related to response to stress
(Ddit4, Cryab) and metabolism. The down-modulation
of Thedc1, with a role in lipid metabolism, was not
Table 2 Functional categories significantly over-
represented in the up- or down-modulated genes at 35
days of age by the effects of in utero exposure to low
dose of BBP
Function GO p-value
Up-modulated signal transduction GO:0007165 6.86E-04
GO:0007242
cell communication GO:0007154 9.62E-04
metabolic process GO:0008152 2.64E-03
GO:0044238
apoptosis GO:0006915 3.68E-03
transport GO:0006810 6.42E-03
cellular process GO:0009987 7.55E-03
other GO:0008015 1.30E-03
GO:0006936 1.34E-03
Down-
modulated
primary metabolic
process
GO:0044238 2.00E-06
GO:0008152,
GO:0006139,
GO:0005975,
GO:0019538
cellular process GO:0009987 3.63E-05
transport GO:0006810 1.44E-04
GO:0006886,
GO:0015031,
GO:0006897,
GO:0016192
cell cycle GO:0007049 1.84E-03
GO:0007067
immune system
process
GO:0002376 2.64E-03
cell-matrix adhesion GO:0007160 3.05E-03
apoptosis GO:0006915 4.63E-03
other GO:0007269 5.80E-03
GO:0007059 6.14E-03
GO, Gene Ontology class.
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the effects of in utero exposure to high dose of BBP
Function GO p-value
Up-modulated metabolic process GO:0008152, 6.71E-14
GO:0044238, GO:0006629, GO:0005975,
GO:0019538, GO:0006800, GO:0006807,
GO:0006519, GO:0006732, GO:0006091,
GO:0006766, GO:0006790, GO:0022904
cell communication GO:0007154 1.04E-09
signaling GO:0007165 2.78E-09
GO:0007242, GO:0007267, GO:0007166
transport GO:0006810 5.14E-09
GO:0006886, GO:0015031, GO:0006897,
GO:0006869, GO:0016192, GO:0006811,
GO:0051180, GO:0008643, GO:0006812
immune system process GO:0002376 4.12E-08
cellular process GO:0009987 1.73E-07
cell adhesion GO:0007155 4.50E-07
GO:0007160, GO:0016337
system process GO:0003008 8.59E-07
GO:0050877, GO:0008015, GO:0007601,
GO:0007268
response to stimulus GO:0050896 3.96E-05
GO:0009605, GO:0006950, GO:0009636
homeostatic process GO:0042592 1.22E-04
GO:0007596,GO:0001678
developmental process GO:0032502 5.03E-04
GO:0009948, GO:0007399, GO:0048731,
GO:0007398
apoptosis GO:0006915 1.91E-03
Down-modulated cellular process GO:0009987 5.88E-18
metabolic process GO:0008152 1.14E-17
GO:0044238, GO:0006139, GO:0019538,
GO:0005975, GO:0006091, GO:0022904
cell cycle GO:0007049 6.21E-13
GO:0007067
cell communication GO:0007154 2.02E-09
GO:0007269
intracellular signaling cascade GO:0007242 1.39E-08
GO:0007165, GO:0007267, GO:0007166
cell motion GO:0006928 8.25E-07
transport GO:0006810 5.83E-06
GO:0008643, GO:0006886, GO:0015031,
GO:0016192
cellular component organization GO:0016043 2.56E-05
GO:0006325, GO:0006996
apoptosis GO:0006915 9.20E-05
GO:0043066
immune system process GO:0002376 1.07E-04
developmental process GO:0032502 5.31E-04
GO:0048731, GO:0007399, GO:0007398
cell adhesion GO:0007155 5.75E-04
GO:0016337, GO:0007160
Moral et al. Environmental Health 2011, 10:5
http://www.ehjournal.net/content/10/1/5
Page 8 of 12confirmed by real time PCR at 35 days although we
found a significant increase in its expression at 50 days
(data not shown). Moreover, some of the genes studied,
such as Cryab, had also a role in metabolism [39].
Modifications in the expression of similar genes (related
to metabolism or oxidative stress) have been also
described in testis of rats exposed prenatally with BBP.
Such modifications are suggested to be related with
Table 3 Functional categories significantly over-represented in the up- or down-modulated genes at 35 days of age by
the effects of in utero exposure to high dose of BBP (Continued)
response to stimulus GO:0050896 2.18E-03
GO:0006950
system process GO:0003008 2.45E-03
GO:0050877, GO:0007601, GO:0007268
Other GO:0000910 2.32E-03
GO:0007276 7.53E-03
GO, Gene Ontology class.
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Figure 3 Gene expression analyses of the mammary gland by real time PCR. Gene expression analyses by real time RT-PCR and
comparison with results from microarrays. Grey bars represent results obtained in the microarrays, black bars represent results obtained in the
real time RT-PCR. Results show the mean fold expression of each treated group related to the mean of the control group. *: statistically
significant changes (p < 0.05); †: changes close to significance (0.1 > p > 0.05).
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Page 9 of 12changes in the hormonal balance of developing fetal tes-
tis [11]. Considering such evidence, our results could
also be a reflection, at least in part, of changes in the
hormonal balance in the BBP treated rats.
Therefore, our data suggest that prenatal exposure to
BBP can have an effect on normal post-natal develop-
ment of the rat. Delayed vaginal opening could be the
result of an altered maturation of the hypothalamic-
gonadal axis for the timing of the onset of puberty.
While the development of the mammary gland under-
goes a critical phase with the initiation of puberty, mod-
ifications in the morphology of the gland and in the
quantity of each specific structure begins before puberty
and continues for a long period of time. The changes in
the morphology and the proliferative index of the mam-
mary gland, more than advanced or retarded growth,
suggest a different pattern in the normal development
of the gland that would affect the windows of suscept-
ibility of this gland. This would increase or decrease the
susceptibility to malignant transformation depending of
the moment when a carcinogenic insult occurs. Such
changes can be supported, at least in part, by modifica-
tions in the gene expression profile of the gland. BBP
exposure down-modulated the expression of genes
related to functions like immunity, apoptosis and also
differentiation markers, which would be in accordance
with a less differentiated gland. Our results also points
out the possibility of a metabolic disruption of this com-
pound. In fact, there is growing evidence that several
pollutants, some of them considered endocrine disrup-
tors such as phthalates, may interact with members of
the PPAR superfamily and interfere with lipid and car-
bohydrate metabolism [40]. Such pollutants are tenta-
tively named “metabolic disrupters”, and are currently of
interest since several human diseases, such as athero-
sclerosis, hyperlipidemia and obesity, often reflect subtle
deregulations of complex metabolic pathways and are
manifested after many years [41].
On the other hand, we need to consider the different
methodological approaches in the interpretation of the
data obtained. We have visualized the number of the
epithelial structures and the proliferation index of such
structures. However, because stromal-epithelial interac-
tions are essential for the development of the mammary
gland, in addition to methodological reasons, gene
expression profile was determined in the whole mam-
mary tissue of the forth gland (with the exception of the
lymph node). Thus, the changes in gene expression
observed can be related to modifications in the biology
of the epithelial (as suggested by the mammary differen-
tiation markers), and stromal cells, such as the fibro-
blasts or adipocytes. Actually, changes in lipid
metabolism may be occurring in the adipose tissue, and
changes in the immune related genes may be a
reflection of modifications in the number, type or func-
tion of infiltrated immune cells. In any case, all these
cell types have an essential role in the development of
the mammary gland, and thus changes in their expres-
sion profile may be of importance in the biology of such
tissue [42,43].
As mentioned above, we have previously reported that
the prenatal exposure to another endocrine disruptor,
bisphenol A (BPA), also induced changes in the mam-
mary gland that were time- and dose-specific [30]. Both
doses tested (25 and 250 μg/kg) caused modification of
the expression of similar clusters of genes (e.g. several
differentiation markers, immune-related genes) that
have also been reported as differentially modulated by
BBP exposure in this work. These evidences suggest that
some genes involved in general and essential processes
may be especially sensitive to the effect of endocrine
disruptors, and taken together, data regarding mammary
gland morphology, proliferative index and gene expres-
sion profile analyses suggest changes in the biology of
the gland that may change its susceptibility to breast
cancer. Even when caution must be applied when com-
paring animal studies with human data, these studies
give further evidence of the potential effect of BBP on
human health. Although the action of this and other
xenobiotics may not be as strong as other steroidal
endocrine disruptors, they are produced in much larger
quantities and population is continuously exposed to
them. Actually BBP exposure in adults has been esti-
m a t e da t2μg/kg body weight/day, and three-old higher
in infants and children [44]. Moreover, urinary concen-
trations of BBP have been detected in > 75% of refer-
ence population, with significantly higher levels in
children and adolescents [45]. The mechanisms by
which this xenobiotic alters mammary gland biology and
gene expression are not still well determined. New stu-
dies are currently underway to elucidate if there are
modifications in the hormonal balance causing such
changes and those are related to the risk of mammary
gland malignant transformation.
Conclusions
The results of this work suggest that prenatal exposure
to BBP can have an effect on normal post-natal develop-
ment of the rat, as characterized by delayed vaginal
opening and modifications in morphology, proliferation
index and gene expression in the mammary gland. Mor-
phology and proliferative rate of this gland suggested
changes in its pattern of development that could affect
the windows of susceptibility to transformation. Prenatal
BBP exposure also induced changes in the gene expres-
sion of the mammary gland long after the end of the
exposure, mainly at the beginning of puberty. Genes
related to immune function, cell signaling, proliferation
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Page 10 of 12and differentiation seem to be particularly sensitive to the
effect of BBP. All these data may be, on the one hand, a
reflection of endocrine disruption, and on the other, an
indicator of changes in the risk of breast cancer.
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Additional file 1: Modulated genes by effect of in utero exposure to
low dose of BBP. List of known up- and down-regulated genes at 35
days of age in mammary glands of rats exposed prenatally to low dose
(120 mg/kg BW) of BBP. For each gene the name, symbol, GeneBank
accession number, fold change expression value (in Log2) versus control
group, and false discovery rate (FDR) is indicated.
Additional file 2: Modulated genes by effect of in utero exposure to
high dose of BBP. List of known up- and down-regulated genes at 35
days of age in mammary glands of rats exposed prenatally to high dose
(500 mg/kg BW) of BBP. For each gene the name, symbol, GeneBank
accession number, fold change expression value (in Log2) versus control
group, and false discovery rate (FDR) is indicated.
Additional file 3: Functional categories analysis of the modulated
genes by effect of in utero exposure to BBP. Detailed functional
categories significantly over- or under-represented in the list of genes
found as modulated at 35 days of age by the effects of in utero exposure
to low (120 mg/kg BW) and high dose high dose (500 mg/kg BW) of
BBP.
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